| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biodiversity | 132 | 2024 | 345 | 19.790 |
Why?
|
| Disease Transmission, Infectious | 38 | 2022 | 560 | 11.400 |
Why?
|
| Mycobacterium tuberculosis | 109 | 2024 | 1930 | 10.700 |
Why?
|
| Coronavirus Infections | 43 | 2020 | 3115 | 8.720 |
Why?
|
| Pneumonia, Viral | 42 | 2020 | 3238 | 8.280 |
Why?
|
| Immunization, Secondary | 17 | 2022 | 373 | 7.450 |
Why?
|
| Communicable Disease Control | 22 | 2022 | 857 | 6.300 |
Why?
|
| Mycobacterium smegmatis | 29 | 2024 | 126 | 6.110 |
Why?
|
| Viral Vaccines | 19 | 2023 | 596 | 6.050 |
Why?
|
| Tuberculosis | 44 | 2023 | 2029 | 5.430 |
Why?
|
| Global Warming | 29 | 2024 | 79 | 5.210 |
Why?
|
| Pandemics | 49 | 2023 | 8750 | 4.730 |
Why?
|
| Antiviral Agents | 20 | 2024 | 3073 | 4.690 |
Why?
|
| Immunization Programs | 9 | 2022 | 267 | 4.430 |
Why?
|
| Temperature | 111 | 2023 | 2234 | 4.110 |
Why?
|
| Bacterial Proteins | 58 | 2024 | 3841 | 4.080 |
Why?
|
| Public Health Practice | 11 | 2022 | 221 | 4.080 |
Why?
|
| Mycobacterium | 16 | 2023 | 252 | 3.980 |
Why?
|
| Editorial Policies | 19 | 2022 | 458 | 3.980 |
Why?
|
| Antitubercular Agents | 35 | 2023 | 1397 | 3.660 |
Why?
|
| Antibodies, Monoclonal | 21 | 2022 | 9253 | 3.100 |
Why?
|
| Adenosine Monophosphate | 7 | 2021 | 232 | 3.100 |
Why?
|
| Periodicals as Topic | 23 | 2022 | 1465 | 3.030 |
Why?
|
| Clinical Laboratory Techniques | 7 | 2020 | 746 | 3.000 |
Why?
|
| Alanine | 8 | 2021 | 614 | 2.880 |
Why?
|
| Antibodies, Viral | 20 | 2022 | 3216 | 2.550 |
Why?
|
| Cell Wall | 19 | 2022 | 421 | 2.480 |
Why?
|
| Journalism, Medical | 4 | 2023 | 73 | 2.480 |
Why?
|
| Biomedical Research | 14 | 2023 | 3464 | 2.410 |
Why?
|
| Fever | 24 | 2021 | 1613 | 2.320 |
Why?
|
| Peptidoglycan | 11 | 2022 | 246 | 2.230 |
Why?
|
| International Cooperation | 13 | 2023 | 1434 | 2.190 |
Why?
|
| Humans | 445 | 2024 | 767998 | 2.160 |
Why?
|
| Clinical Trials as Topic | 19 | 2022 | 8052 | 2.100 |
Why?
|
| Masks | 4 | 2022 | 214 | 2.050 |
Why?
|
| Vaccination | 16 | 2022 | 3437 | 2.050 |
Why?
|
| N-Acetylmuramoyl-L-alanine Amidase | 5 | 2019 | 48 | 1.970 |
Why?
|
| Hydroxychloroquine | 6 | 2020 | 426 | 1.940 |
Why?
|
| United States Food and Drug Administration | 8 | 2024 | 1671 | 1.920 |
Why?
|
| Public Health | 14 | 2023 | 2682 | 1.890 |
Why?
|
| Genome, Bacterial | 17 | 2024 | 796 | 1.830 |
Why?
|
| Immunocompromised Host | 5 | 2022 | 863 | 1.820 |
Why?
|
| Immunization, Passive | 9 | 2021 | 619 | 1.800 |
Why?
|
| Influenza in Birds | 2 | 2024 | 76 | 1.770 |
Why?
|
| Federal Government | 4 | 2024 | 266 | 1.770 |
Why?
|
| Climate Change | 16 | 2024 | 509 | 1.750 |
Why?
|
| Birds | 2 | 2024 | 166 | 1.750 |
Why?
|
| Information Dissemination | 5 | 2021 | 1142 | 1.660 |
Why?
|
| Antibiotics, Antitubercular | 5 | 2022 | 100 | 1.660 |
Why?
|
| Conservation of Natural Resources | 10 | 2022 | 209 | 1.600 |
Why?
|
| Drug Approval | 7 | 2024 | 820 | 1.570 |
Why?
|
| Disease Outbreaks | 7 | 2024 | 1761 | 1.560 |
Why?
|
| Antibodies, Neutralizing | 14 | 2022 | 2011 | 1.550 |
Why?
|
| Mass Media | 4 | 2021 | 303 | 1.530 |
Why?
|
| Drug Resistance, Bacterial | 15 | 2022 | 1063 | 1.520 |
Why?
|
| DNA Transposable Elements | 20 | 2017 | 764 | 1.430 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2021 | 1804 | 1.410 |
Why?
|
| Communication | 8 | 2022 | 3905 | 1.400 |
Why?
|
| Drug Discovery | 12 | 2022 | 1068 | 1.380 |
Why?
|
| Cell Division | 11 | 2019 | 4473 | 1.370 |
Why?
|
| Immunity, Mucosal | 3 | 2022 | 498 | 1.370 |
Why?
|
| Disclosure | 13 | 2020 | 755 | 1.360 |
Why?
|
| Quarantine | 6 | 2021 | 186 | 1.360 |
Why?
|
| Dexamethasone | 7 | 2021 | 1964 | 1.350 |
Why?
|
| Virulence | 22 | 2022 | 1297 | 1.340 |
Why?
|
| Rifampin | 5 | 2021 | 352 | 1.340 |
Why?
|
| Cocaine-Related Disorders | 18 | 2024 | 458 | 1.330 |
Why?
|
| Contact Tracing | 3 | 2020 | 275 | 1.320 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2021 | 224 | 1.320 |
Why?
|
| Vaccines | 6 | 2022 | 842 | 1.290 |
Why?
|
| Social Justice | 2 | 2024 | 487 | 1.290 |
Why?
|
| Politics | 4 | 2024 | 822 | 1.280 |
Why?
|
| Ethics, Medical | 2 | 2024 | 785 | 1.250 |
Why?
|
| Genes, Bacterial | 17 | 2020 | 1076 | 1.210 |
Why?
|
| World Health Organization | 4 | 2022 | 1328 | 1.200 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 5520 | 1.200 |
Why?
|
| Healthcare Disparities | 7 | 2022 | 3415 | 1.180 |
Why?
|
| Anti-Bacterial Agents | 19 | 2024 | 7469 | 1.180 |
Why?
|
| Patient Care | 4 | 2022 | 629 | 1.170 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1595 | 1.160 |
Why?
|
| Hemorrhagic Fever, Ebola | 5 | 2022 | 424 | 1.150 |
Why?
|
| Bacteria | 7 | 2014 | 2216 | 1.120 |
Why?
|
| Public Policy | 2 | 2022 | 552 | 1.100 |
Why?
|
| Medicine | 3 | 2024 | 945 | 1.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2021 | 667 | 1.080 |
Why?
|
| Evolution, Molecular | 8 | 2022 | 1896 | 1.070 |
Why?
|
| Microbial Sensitivity Tests | 17 | 2024 | 1966 | 1.050 |
Why?
|
| Mutagenesis, Insertional | 13 | 2017 | 661 | 1.040 |
Why?
|
| Immunity, Active | 2 | 2023 | 58 | 1.040 |
Why?
|
| Virus Replication | 12 | 2022 | 2458 | 1.040 |
Why?
|
| Bacteriophages | 8 | 2023 | 382 | 1.020 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 621 | 0.990 |
Why?
|
| Conflict of Interest | 9 | 2020 | 556 | 0.980 |
Why?
|
| Mass Vaccination | 3 | 2021 | 111 | 0.980 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2020 | 843 | 0.970 |
Why?
|
| Emergencies | 6 | 2023 | 1224 | 0.960 |
Why?
|
| Minority Groups | 3 | 2021 | 1217 | 0.960 |
Why?
|
| Israel | 6 | 2021 | 726 | 0.960 |
Why?
|
| Consumer Health Information | 3 | 2021 | 215 | 0.940 |
Why?
|
| Drug Resistance, Viral | 4 | 2022 | 869 | 0.940 |
Why?
|
| Vaccines, Synthetic | 3 | 2022 | 621 | 0.930 |
Why?
|
| Glucocorticoids | 4 | 2021 | 2166 | 0.930 |
Why?
|
| Genetic Vectors | 12 | 2022 | 3402 | 0.930 |
Why?
|
| United States | 40 | 2024 | 73033 | 0.930 |
Why?
|
| Ritonavir | 3 | 2022 | 331 | 0.910 |
Why?
|
| Influenza, Human | 3 | 2024 | 1541 | 0.910 |
Why?
|
| History of Medicine | 1 | 2024 | 42 | 0.900 |
Why?
|
| Thrombosis | 4 | 2021 | 2957 | 0.900 |
Why?
|
| Serine Endopeptidases | 5 | 2019 | 1027 | 0.890 |
Why?
|
| Myocarditis | 2 | 2021 | 802 | 0.880 |
Why?
|
| Attitude to Health | 3 | 2021 | 2024 | 0.880 |
Why?
|
| Endopeptidase Clp | 4 | 2021 | 42 | 0.860 |
Why?
|
| Drug Industry | 4 | 2022 | 791 | 0.850 |
Why?
|
| Emergency Service, Hospital | 32 | 2021 | 7940 | 0.840 |
Why?
|
| State Government | 3 | 2021 | 388 | 0.830 |
Why?
|
| Infection Control | 5 | 2021 | 985 | 0.830 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 21 | 0.820 |
Why?
|
| Health Education | 7 | 2022 | 1059 | 0.820 |
Why?
|
| Vaccines, Combined | 1 | 2022 | 70 | 0.810 |
Why?
|
| Penicillin-Binding Proteins | 4 | 2022 | 152 | 0.800 |
Why?
|
| Fossil Fuels | 1 | 2022 | 53 | 0.790 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2023 | 88 | 0.790 |
Why?
|
| Hydroxylamines | 1 | 2021 | 39 | 0.780 |
Why?
|
| Antitoxins | 1 | 2022 | 75 | 0.780 |
Why?
|
| Cytidine | 1 | 2021 | 60 | 0.770 |
Why?
|
| Developed Countries | 8 | 2022 | 454 | 0.760 |
Why?
|
| Hospitalization | 7 | 2022 | 10843 | 0.750 |
Why?
|
| Genes, Essential | 7 | 2019 | 185 | 0.750 |
Why?
|
| Lactams | 1 | 2022 | 159 | 0.740 |
Why?
|
| Publishing | 4 | 2024 | 837 | 0.740 |
Why?
|
| Patient Selection | 3 | 2022 | 4258 | 0.740 |
Why?
|
| Mandatory Programs | 1 | 2021 | 86 | 0.730 |
Why?
|
| Tobacco Industry | 1 | 2022 | 139 | 0.720 |
Why?
|
| Health Care Rationing | 2 | 2021 | 435 | 0.720 |
Why?
|
| Asymptomatic Diseases | 5 | 2021 | 590 | 0.720 |
Why?
|
| Mutation | 27 | 2023 | 30214 | 0.720 |
Why?
|
| Granuloma | 2 | 2016 | 329 | 0.720 |
Why?
|
| Cocaine | 12 | 2024 | 947 | 0.710 |
Why?
|
| Oxazoles | 5 | 2015 | 199 | 0.710 |
Why?
|
| Time Factors | 23 | 2023 | 40210 | 0.710 |
Why?
|
| Host-Pathogen Interactions | 6 | 2019 | 1469 | 0.710 |
Why?
|
| Leucine | 1 | 2022 | 547 | 0.700 |
Why?
|
| Social Isolation | 2 | 2021 | 366 | 0.700 |
Why?
|
| Anti-Infective Agents | 2 | 2020 | 983 | 0.690 |
Why?
|
| Proline | 1 | 2022 | 455 | 0.690 |
Why?
|
| Epoprostenol | 1 | 2021 | 246 | 0.690 |
Why?
|
| Adenoviridae | 5 | 2021 | 1092 | 0.690 |
Why?
|
| Cytoplasm | 2 | 2016 | 1505 | 0.680 |
Why?
|
| Choice Behavior | 5 | 2022 | 848 | 0.680 |
Why?
|
| Viral Load | 8 | 2021 | 3396 | 0.680 |
Why?
|
| Latent Tuberculosis | 4 | 2019 | 224 | 0.680 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 554 | 0.670 |
Why?
|
| Virulence Factors | 8 | 2020 | 502 | 0.670 |
Why?
|
| Oxygen | 3 | 2021 | 4269 | 0.670 |
Why?
|
| Organelles | 1 | 2021 | 265 | 0.670 |
Why?
|
| Epidemics | 4 | 2021 | 517 | 0.670 |
Why?
|
| Environmental Health | 5 | 2021 | 298 | 0.660 |
Why?
|
| Science | 1 | 2022 | 236 | 0.660 |
Why?
|
| Periplasmic Proteins | 1 | 2019 | 25 | 0.660 |
Why?
|
| Mandatory Reporting | 1 | 2020 | 123 | 0.650 |
Why?
|
| Azetidines | 1 | 2020 | 152 | 0.650 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 187 | 0.650 |
Why?
|
| Microbial Viability | 6 | 2019 | 237 | 0.650 |
Why?
|
| South Africa | 6 | 2022 | 1873 | 0.650 |
Why?
|
| Disaster Planning | 5 | 2024 | 559 | 0.640 |
Why?
|
| Authorship | 10 | 2020 | 289 | 0.640 |
Why?
|
| Health Communication | 1 | 2022 | 216 | 0.640 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 718 | 0.630 |
Why?
|
| Tryptophan | 4 | 2021 | 482 | 0.630 |
Why?
|
| Mutagenesis | 6 | 2022 | 1228 | 0.620 |
Why?
|
| Mycobacterium bovis | 7 | 2023 | 148 | 0.620 |
Why?
|
| Prodrugs | 3 | 2017 | 274 | 0.620 |
Why?
|
| Research Support as Topic | 3 | 2021 | 697 | 0.610 |
Why?
|
| Private Sector | 1 | 2021 | 396 | 0.610 |
Why?
|
| Macrophages | 18 | 2023 | 5798 | 0.610 |
Why?
|
| Gene Expression Regulation, Bacterial | 12 | 2024 | 1137 | 0.610 |
Why?
|
| Health Planning | 1 | 2020 | 233 | 0.610 |
Why?
|
| Viruses | 1 | 2022 | 373 | 0.610 |
Why?
|
| Mycobacterium marinum | 2 | 2009 | 29 | 0.610 |
Why?
|
| Iron | 6 | 2019 | 1813 | 0.600 |
Why?
|
| Workload | 1 | 2024 | 849 | 0.600 |
Why?
|
| Animal Experimentation | 1 | 2018 | 46 | 0.590 |
Why?
|
| Nitriles | 2 | 2022 | 980 | 0.590 |
Why?
|
| United Nations | 7 | 2022 | 151 | 0.590 |
Why?
|
| Adaptive Immunity | 3 | 2020 | 733 | 0.580 |
Why?
|
| Ethionamide | 1 | 2017 | 11 | 0.580 |
Why?
|
| Cultural Diversity | 1 | 2021 | 373 | 0.580 |
Why?
|
| Pyrazoles | 2 | 2020 | 2028 | 0.570 |
Why?
|
| Immunity, Herd | 3 | 2022 | 48 | 0.570 |
Why?
|
| Lipid A | 2 | 2015 | 70 | 0.570 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 86 | 0.570 |
Why?
|
| Purines | 1 | 2020 | 615 | 0.560 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 618 | 0.560 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.560 |
Why?
|
| Molecular Biology | 2 | 2014 | 573 | 0.560 |
Why?
|
| Spiro Compounds | 1 | 2017 | 69 | 0.560 |
Why?
|
| Bacterial Toxins | 2 | 2022 | 922 | 0.560 |
Why?
|
| Health Resources | 2 | 2021 | 950 | 0.560 |
Why?
|
| Heat-Shock Proteins | 3 | 2020 | 797 | 0.560 |
Why?
|
| Vaccines, Attenuated | 4 | 2020 | 314 | 0.550 |
Why?
|
| Thrombocytopenia | 6 | 2021 | 1178 | 0.550 |
Why?
|
| Vaccines, Inactivated | 3 | 2021 | 186 | 0.540 |
Why?
|
| Drug Design | 7 | 2021 | 1045 | 0.540 |
Why?
|
| History, 21st Century | 4 | 2024 | 1572 | 0.540 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 377 | 0.530 |
Why?
|
| Research Personnel | 1 | 2021 | 589 | 0.530 |
Why?
|
| Biological Evolution | 1 | 2022 | 1076 | 0.530 |
Why?
|
| Escherichia coli | 12 | 2019 | 4215 | 0.520 |
Why?
|
| Nursing Homes | 2 | 2021 | 1084 | 0.510 |
Why?
|
| Isoxazoles | 1 | 2017 | 233 | 0.500 |
Why?
|
| Health Personnel | 7 | 2023 | 3387 | 0.500 |
Why?
|
| Specimen Handling | 1 | 2020 | 708 | 0.500 |
Why?
|
| Genetic Variation | 5 | 2021 | 6612 | 0.500 |
Why?
|
| Research Design | 5 | 2022 | 6212 | 0.490 |
Why?
|
| Endopeptidases | 2 | 2010 | 763 | 0.490 |
Why?
|
| Ebolavirus | 2 | 2014 | 250 | 0.490 |
Why?
|
| Health Policy | 3 | 2022 | 2698 | 0.490 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2022 | 1801 | 0.480 |
Why?
|
| Interferon-gamma | 4 | 2013 | 3159 | 0.480 |
Why?
|
| Isoniazid | 2 | 2014 | 288 | 0.480 |
Why?
|
| Drug Evaluation | 3 | 2020 | 642 | 0.480 |
Why?
|
| Commerce | 1 | 2020 | 614 | 0.470 |
Why?
|
| Molecular Imaging | 1 | 2021 | 827 | 0.470 |
Why?
|
| Public Health Administration | 3 | 2022 | 242 | 0.470 |
Why?
|
| Genetics, Microbial | 1 | 2014 | 53 | 0.470 |
Why?
|
| Multienzyme Complexes | 3 | 2015 | 664 | 0.470 |
Why?
|
| Mutagenesis, Site-Directed | 6 | 2019 | 1683 | 0.470 |
Why?
|
| Treatment Outcome | 20 | 2022 | 65360 | 0.460 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1883 | 0.460 |
Why?
|
| Animals | 71 | 2024 | 169225 | 0.460 |
Why?
|
| Eicosanoids | 1 | 2016 | 284 | 0.450 |
Why?
|
| Membrane Transport Proteins | 3 | 2016 | 1037 | 0.450 |
Why?
|
| Siderophores | 4 | 2019 | 61 | 0.450 |
Why?
|
| Communicable Diseases | 1 | 2022 | 874 | 0.450 |
Why?
|
| Bacterial Secretion Systems | 1 | 2014 | 35 | 0.450 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 527 | 0.450 |
Why?
|
| Iron Chelating Agents | 1 | 2015 | 141 | 0.450 |
Why?
|
| Cell Polarity | 1 | 2017 | 639 | 0.440 |
Why?
|
| Escherichia coli Proteins | 5 | 2018 | 1058 | 0.440 |
Why?
|
| Nuclear Warfare | 2 | 2023 | 30 | 0.440 |
Why?
|
| Antigens, Bacterial | 7 | 2023 | 1150 | 0.430 |
Why?
|
| Mining | 1 | 2014 | 93 | 0.430 |
Why?
|
| Oxygen Inhalation Therapy | 3 | 2021 | 418 | 0.430 |
Why?
|
| Antigens, Viral | 4 | 2021 | 995 | 0.430 |
Why?
|
| Physician's Role | 1 | 2020 | 925 | 0.430 |
Why?
|
| Inflammation | 6 | 2024 | 10872 | 0.430 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2024 | 117 | 0.420 |
Why?
|
| Lipoproteins | 4 | 2019 | 879 | 0.420 |
Why?
|
| Radiology | 6 | 2024 | 2104 | 0.420 |
Why?
|
| Acyltransferases | 2 | 2017 | 306 | 0.420 |
Why?
|
| Faculty, Medical | 1 | 2021 | 1225 | 0.410 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 211 | 0.410 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 238 | 0.410 |
Why?
|
| Drug Therapy, Combination | 5 | 2022 | 6314 | 0.410 |
Why?
|
| Goals | 1 | 2018 | 717 | 0.410 |
Why?
|
| Mycobacteriophages | 2 | 2023 | 19 | 0.410 |
Why?
|
| Leadership | 2 | 2021 | 1397 | 0.400 |
Why?
|
| Endotoxins | 1 | 2015 | 519 | 0.400 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 1240 | 0.400 |
Why?
|
| Pyrimidinones | 1 | 2015 | 386 | 0.400 |
Why?
|
| Oligopeptides | 6 | 2021 | 1194 | 0.400 |
Why?
|
| Self Administration | 9 | 2024 | 386 | 0.400 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2008 | 3798 | 0.390 |
Why?
|
| Mycobacterium Infections | 4 | 2018 | 122 | 0.390 |
Why?
|
| Cell Physiological Phenomena | 1 | 2013 | 152 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 7 | 2014 | 6070 | 0.390 |
Why?
|
| Molecular Sequence Data | 25 | 2015 | 17617 | 0.390 |
Why?
|
| Microcephaly | 1 | 2016 | 426 | 0.390 |
Why?
|
| Trust | 3 | 2021 | 532 | 0.380 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 2726 | 0.380 |
Why?
|
| RNA, Transfer | 3 | 2023 | 284 | 0.380 |
Why?
|
| History, 19th Century | 2 | 2024 | 714 | 0.380 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 2029 | 0.380 |
Why?
|
| Enzyme Inhibitors | 6 | 2021 | 3726 | 0.370 |
Why?
|
| Age Factors | 9 | 2021 | 18405 | 0.370 |
Why?
|
| Peptide Hydrolases | 3 | 2012 | 610 | 0.370 |
Why?
|
| Pneumonia | 1 | 2023 | 2164 | 0.370 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 14718 | 0.370 |
Why?
|
| Selection, Genetic | 3 | 2022 | 877 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 3231 | 0.360 |
Why?
|
| Sulfonamides | 1 | 2020 | 1982 | 0.360 |
Why?
|
| Endemic Diseases | 2 | 2022 | 191 | 0.360 |
Why?
|
| History, 20th Century | 3 | 2024 | 2765 | 0.360 |
Why?
|
| Protein Biosynthesis | 2 | 2018 | 2094 | 0.360 |
Why?
|
| Forecasting | 4 | 2023 | 2945 | 0.360 |
Why?
|
| Multigene Family | 1 | 2014 | 1081 | 0.350 |
Why?
|
| Fetal Diseases | 1 | 2016 | 916 | 0.350 |
Why?
|
| Disease Reservoirs | 2 | 2021 | 123 | 0.350 |
Why?
|
| Aminosalicylic Acid | 2 | 2013 | 20 | 0.350 |
Why?
|
| Hydrolases | 2 | 2023 | 146 | 0.350 |
Why?
|
| Child | 13 | 2022 | 80905 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 1605 | 0.340 |
Why?
|
| Peptidoglycan Glycosyltransferase | 1 | 2010 | 66 | 0.340 |
Why?
|
| Lipids | 5 | 2019 | 3342 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2022 | 15944 | 0.340 |
Why?
|
| Virus Shedding | 2 | 2020 | 110 | 0.340 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 380 | 0.340 |
Why?
|
| Gene Library | 5 | 2017 | 1065 | 0.340 |
Why?
|
| Lipopolysaccharides | 3 | 2015 | 2219 | 0.340 |
Why?
|
| Physician Assistants | 2 | 2022 | 190 | 0.340 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 1966 | 0.330 |
Why?
|
| Smoking | 6 | 2022 | 9087 | 0.330 |
Why?
|
| Africa | 2 | 2022 | 725 | 0.330 |
Why?
|
| Developing Countries | 1 | 2022 | 2914 | 0.320 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 966 | 0.320 |
Why?
|
| Camptothecin | 4 | 1999 | 599 | 0.320 |
Why?
|
| Nurse Practitioners | 2 | 2022 | 271 | 0.320 |
Why?
|
| Comorbidity | 3 | 2020 | 10590 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 2421 | 0.320 |
Why?
|
| Reactive Oxygen Species | 3 | 2016 | 2149 | 0.310 |
Why?
|
| Pyrazinamide | 2 | 2020 | 60 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 2 | 2021 | 2708 | 0.310 |
Why?
|
| Amino Acids | 3 | 2018 | 1716 | 0.310 |
Why?
|
| Plasmids | 7 | 2008 | 2269 | 0.310 |
Why?
|
| Pregnancy | 6 | 2021 | 30244 | 0.310 |
Why?
|
| DNA, Bacterial | 7 | 2021 | 1478 | 0.310 |
Why?
|
| Air Pollution | 1 | 2022 | 2378 | 0.300 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2666 | 0.300 |
Why?
|
| Placebos | 4 | 2021 | 1667 | 0.300 |
Why?
|
| Aminoglycosides | 2 | 2018 | 161 | 0.300 |
Why?
|
| DNA Topoisomerases, Type I | 3 | 1999 | 108 | 0.300 |
Why?
|
| Air Pollutants | 1 | 2022 | 2920 | 0.300 |
Why?
|
| Infusions, Intravenous | 5 | 2021 | 2227 | 0.300 |
Why?
|
| Mycolic Acids | 3 | 2019 | 54 | 0.300 |
Why?
|
| Chemoprevention | 2 | 2020 | 327 | 0.290 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2010 | 1901 | 0.290 |
Why?
|
| Tuberculosis Vaccines | 3 | 2020 | 48 | 0.290 |
Why?
|
| Cytokines | 3 | 2021 | 7453 | 0.290 |
Why?
|
| Prisoners | 2 | 2021 | 316 | 0.290 |
Why?
|
| Bacteremia | 1 | 2014 | 986 | 0.290 |
Why?
|
| Neoplasms | 8 | 2024 | 22369 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 12 | 2013 | 4785 | 0.280 |
Why?
|
| Phagosomes | 2 | 2019 | 198 | 0.280 |
Why?
|
| Carrier State | 2 | 2021 | 529 | 0.280 |
Why?
|
| RNA, Bacterial | 4 | 2015 | 393 | 0.280 |
Why?
|
| Drug Interactions | 2 | 2022 | 1419 | 0.280 |
Why?
|
| Piperidines | 3 | 2021 | 1667 | 0.280 |
Why?
|
| Transcription, Genetic | 10 | 2017 | 7613 | 0.280 |
Why?
|
| Plasma | 2 | 2020 | 584 | 0.280 |
Why?
|
| Chromosomes, Bacterial | 3 | 2005 | 281 | 0.280 |
Why?
|
| Base Sequence | 18 | 2012 | 12417 | 0.280 |
Why?
|
| Gene Expression Profiling | 5 | 2012 | 9536 | 0.280 |
Why?
|
| Mass Spectrometry | 7 | 2016 | 2202 | 0.280 |
Why?
|
| Repressor Proteins | 3 | 2017 | 2982 | 0.270 |
Why?
|
| Disease Management | 1 | 2017 | 2533 | 0.270 |
Why?
|
| Transformation, Bacterial | 2 | 2007 | 79 | 0.270 |
Why?
|
| Biotin | 2 | 2023 | 256 | 0.270 |
Why?
|
| Transposases | 4 | 2001 | 106 | 0.270 |
Why?
|
| Phenotype | 9 | 2017 | 16723 | 0.270 |
Why?
|
| Hot Temperature | 3 | 2021 | 1442 | 0.270 |
Why?
|
| Government Regulation | 2 | 2022 | 525 | 0.270 |
Why?
|
| Transcription Factors | 7 | 2022 | 12165 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 10396 | 0.270 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2010 | 827 | 0.270 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2022 | 944 | 0.260 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2016 | 505 | 0.260 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 1305 | 0.260 |
Why?
|
| Gene Deletion | 5 | 2019 | 2673 | 0.260 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 4857 | 0.260 |
Why?
|
| Immunity, Cellular | 3 | 2022 | 1561 | 0.260 |
Why?
|
| Mice | 37 | 2023 | 82024 | 0.260 |
Why?
|
| Administration, Oral | 4 | 2023 | 4030 | 0.260 |
Why?
|
| Computational Biology | 2 | 2016 | 3568 | 0.250 |
Why?
|
| Immunity | 2 | 2022 | 1004 | 0.250 |
Why?
|
| Glycoproteins | 1 | 2013 | 2201 | 0.250 |
Why?
|
| Single-Cell Analysis | 1 | 2017 | 2543 | 0.250 |
Why?
|
| Scientific Misconduct | 2 | 2023 | 77 | 0.250 |
Why?
|
| Hydroxamic Acids | 2 | 2010 | 483 | 0.250 |
Why?
|
| Ethics, Professional | 2 | 2023 | 100 | 0.250 |
Why?
|
| Recurrence | 3 | 2022 | 8507 | 0.250 |
Why?
|
| Prophages | 2 | 2023 | 39 | 0.240 |
Why?
|
| Tissue Donors | 1 | 2015 | 2385 | 0.240 |
Why?
|
| Bacterial Vaccines | 2 | 2007 | 400 | 0.240 |
Why?
|
| Aspartic Acid | 2 | 2020 | 577 | 0.240 |
Why?
|
| Nicotinamide-Nucleotide Adenylyltransferase | 2 | 2015 | 12 | 0.240 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 1396 | 0.230 |
Why?
|
| Disulfides | 3 | 2019 | 466 | 0.230 |
Why?
|
| Immunotherapy | 1 | 2020 | 4748 | 0.230 |
Why?
|
| Drug Combinations | 2 | 2022 | 2088 | 0.230 |
Why?
|
| Mass Screening | 1 | 2020 | 5458 | 0.230 |
Why?
|
| Muramidase | 2 | 2019 | 163 | 0.230 |
Why?
|
| Government | 2 | 2022 | 161 | 0.230 |
Why?
|
| DNA-Directed RNA Polymerases | 3 | 2014 | 366 | 0.230 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 13658 | 0.230 |
Why?
|
| Europe | 2 | 2022 | 3438 | 0.230 |
Why?
|
| RNA, Messenger | 12 | 2020 | 12797 | 0.230 |
Why?
|
| Cholesterol | 1 | 2013 | 2914 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2020 | 1335 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2013 | 4415 | 0.220 |
Why?
|
| Reproductive Health Services | 1 | 2024 | 90 | 0.220 |
Why?
|
| Vibrio cholerae | 5 | 2014 | 793 | 0.220 |
Why?
|
| Hydrolysis | 4 | 2014 | 646 | 0.210 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 2040 | 0.210 |
Why?
|
| Brazil | 3 | 2021 | 1250 | 0.210 |
Why?
|
| Protein Conformation | 9 | 2020 | 3956 | 0.210 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 255 | 0.210 |
Why?
|
| Operon | 4 | 2024 | 371 | 0.210 |
Why?
|
| Anticoagulants | 4 | 2021 | 4854 | 0.210 |
Why?
|
| Mycobacterium leprae | 1 | 2003 | 95 | 0.210 |
Why?
|
| Peptide Library | 2 | 2015 | 351 | 0.210 |
Why?
|
| Chromosome Mapping | 6 | 2014 | 4618 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2021 | 24317 | 0.210 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2023 | 99 | 0.210 |
Why?
|
| Water Purification | 1 | 2023 | 61 | 0.210 |
Why?
|
| Multiprotein Complexes | 2 | 2008 | 1110 | 0.210 |
Why?
|
| Virus Physiological Phenomena | 1 | 2022 | 15 | 0.200 |
Why?
|
| Government Programs | 2 | 2021 | 278 | 0.200 |
Why?
|
| Genes, jun | 5 | 1993 | 69 | 0.200 |
Why?
|
| Group Practice | 1 | 2023 | 149 | 0.200 |
Why?
|
| Monkeypox virus | 1 | 2022 | 43 | 0.200 |
Why?
|
| Gene Targeting | 2 | 2003 | 841 | 0.200 |
Why?
|
| Immune System | 1 | 2008 | 799 | 0.200 |
Why?
|
| Congresses as Topic | 3 | 2021 | 812 | 0.200 |
Why?
|
| Interleukin-6 | 5 | 2021 | 3228 | 0.200 |
Why?
|
| Asthma | 1 | 2021 | 6273 | 0.200 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2021 | 36 | 0.200 |
Why?
|
| RNA, Viral | 2 | 2020 | 2871 | 0.200 |
Why?
|
| Biosynthetic Pathways | 2 | 2013 | 138 | 0.200 |
Why?
|
| Qatar | 1 | 2021 | 40 | 0.190 |
Why?
|
| Webcasts as Topic | 1 | 2022 | 21 | 0.190 |
Why?
|
| T-Lymphocytes | 4 | 2022 | 10264 | 0.190 |
Why?
|
| Peptides | 4 | 2023 | 4354 | 0.190 |
Why?
|
| Uridine | 1 | 2021 | 135 | 0.190 |
Why?
|
| Bahamas | 1 | 2021 | 9 | 0.190 |
Why?
|
| Protein Binding | 11 | 2021 | 9343 | 0.190 |
Why?
|
| Cell Cycle | 3 | 2021 | 2932 | 0.190 |
Why?
|
| Gene Expression | 5 | 2017 | 7597 | 0.190 |
Why?
|
| Crystallography, X-Ray | 6 | 2019 | 1951 | 0.180 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2230 | 0.180 |
Why?
|
| Virginia | 1 | 2021 | 115 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2021 | 1168 | 0.180 |
Why?
|
| Amino Acid Sequence | 12 | 2015 | 13420 | 0.180 |
Why?
|
| Environmental Pollution | 1 | 2022 | 125 | 0.180 |
Why?
|
| Education, Distance | 2 | 2022 | 260 | 0.180 |
Why?
|
| Platelet Factor 4 | 1 | 2021 | 132 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 2801 | 0.180 |
Why?
|
| Ireland | 1 | 2021 | 171 | 0.180 |
Why?
|
| Consumer Product Safety | 1 | 2021 | 122 | 0.180 |
Why?
|
| DNA Replication | 4 | 2021 | 1427 | 0.180 |
Why?
|
| Hong Kong | 1 | 2021 | 170 | 0.180 |
Why?
|
| Azabicyclo Compounds | 1 | 2021 | 68 | 0.180 |
Why?
|
| Civil Rights | 1 | 2021 | 131 | 0.180 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 2299 | 0.180 |
Why?
|
| Serology | 1 | 2020 | 7 | 0.180 |
Why?
|
| Quinazolines | 2 | 2021 | 1369 | 0.170 |
Why?
|
| Carbon | 2 | 2022 | 673 | 0.170 |
Why?
|
| Genetic Complementation Test | 2 | 2014 | 557 | 0.170 |
Why?
|
| Ships | 1 | 2020 | 53 | 0.170 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2020 | 361 | 0.170 |
Why?
|
| Bioethical Issues | 1 | 2021 | 119 | 0.170 |
Why?
|
| Female | 45 | 2024 | 397102 | 0.170 |
Why?
|
| Compassionate Use Trials | 1 | 2020 | 50 | 0.170 |
Why?
|
| Iceland | 1 | 2020 | 183 | 0.170 |
Why?
|
| History, 18th Century | 1 | 2020 | 206 | 0.170 |
Why?
|
| Population Surveillance | 2 | 2021 | 2594 | 0.170 |
Why?
|
| Protein Interaction Mapping | 2 | 2014 | 622 | 0.170 |
Why?
|
| Neutralization Tests | 1 | 2022 | 739 | 0.170 |
Why?
|
| Carboxy-Lyases | 1 | 2020 | 85 | 0.170 |
Why?
|
| Recombination, Genetic | 3 | 2014 | 1525 | 0.170 |
Why?
|
| Prejudice | 1 | 2024 | 574 | 0.170 |
Why?
|
| Methylmalonyl-CoA Mutase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 235 | 0.170 |
Why?
|
| Affect | 3 | 2024 | 1495 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 1605 | 0.170 |
Why?
|
| Vehicle Emissions | 2 | 2021 | 651 | 0.170 |
Why?
|
| Hydrazines | 1 | 2021 | 223 | 0.170 |
Why?
|
| Civil Defense | 1 | 2021 | 115 | 0.170 |
Why?
|
| Coenzyme A | 1 | 2019 | 39 | 0.170 |
Why?
|
| Immunization Schedule | 1 | 2021 | 228 | 0.170 |
Why?
|
| Secretory Pathway | 2 | 2009 | 53 | 0.170 |
Why?
|
| Folic Acid | 2 | 2019 | 1337 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 4271 | 0.170 |
Why?
|
| Succinates | 1 | 2019 | 83 | 0.170 |
Why?
|
| Mannosyltransferases | 1 | 2019 | 24 | 0.170 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 686 | 0.170 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2020 | 123 | 0.170 |
Why?
|
| PDZ Domains | 1 | 2019 | 23 | 0.160 |
Why?
|
| Folic Acid Antagonists | 2 | 2013 | 74 | 0.160 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2024 | 1140 | 0.160 |
Why?
|
| Germany | 1 | 2022 | 882 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 617 | 0.160 |
Why?
|
| Washington | 1 | 2020 | 315 | 0.160 |
Why?
|
| BCG Vaccine | 3 | 2023 | 381 | 0.160 |
Why?
|
| Quinolines | 1 | 2005 | 770 | 0.160 |
Why?
|
| Genetic Loci | 3 | 2020 | 2629 | 0.160 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 279 | 0.160 |
Why?
|
| Ubiquitin | 1 | 2004 | 843 | 0.160 |
Why?
|
| Antacids | 1 | 2019 | 94 | 0.160 |
Why?
|
| Bacillus subtilis | 3 | 2019 | 356 | 0.160 |
Why?
|
| Molecular Structure | 6 | 2021 | 1883 | 0.160 |
Why?
|
| Cyclonic Storms | 1 | 2021 | 121 | 0.160 |
Why?
|
| Amino Acid Substitution | 3 | 2014 | 1743 | 0.160 |
Why?
|
| Health Status Disparities | 2 | 2021 | 1885 | 0.160 |
Why?
|
| Coronavirus | 1 | 2021 | 156 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2021 | 3046 | 0.160 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1999 | 70 | 0.160 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 136 | 0.160 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 329 | 0.160 |
Why?
|
| Proteomics | 4 | 2016 | 3912 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2013 | 287 | 0.160 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 116 | 0.160 |
Why?
|
| Treatment Failure | 3 | 2022 | 2660 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2017 | 3669 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 201 | 0.160 |
Why?
|
| Fluorescence | 2 | 2018 | 757 | 0.160 |
Why?
|
| Genomics | 6 | 2022 | 5925 | 0.160 |
Why?
|
| Nitrogen | 1 | 2020 | 345 | 0.160 |
Why?
|
| Disease Models, Animal | 9 | 2022 | 18345 | 0.160 |
Why?
|
| Models, Molecular | 7 | 2019 | 5402 | 0.150 |
Why?
|
| Enterotoxigenic Escherichia coli | 1 | 2018 | 32 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2011 | 296 | 0.150 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 414 | 0.150 |
Why?
|
| Health | 1 | 2021 | 398 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 18069 | 0.150 |
Why?
|
| China | 2 | 2021 | 2395 | 0.150 |
Why?
|
| Religion | 1 | 2021 | 376 | 0.150 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 1311 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 22381 | 0.150 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2018 | 84 | 0.150 |
Why?
|
| Amoeba | 1 | 2018 | 20 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 430 | 0.150 |
Why?
|
| Adult | 32 | 2024 | 223577 | 0.150 |
Why?
|
| Oligosaccharides | 1 | 2020 | 407 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2021 | 854 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2020 | 382 | 0.150 |
Why?
|
| DNA-Binding Proteins | 8 | 2021 | 9614 | 0.150 |
Why?
|
| Equipment and Supplies | 1 | 2020 | 274 | 0.150 |
Why?
|
| Piperazines | 4 | 2014 | 2552 | 0.150 |
Why?
|
| Drug Resistance, Microbial | 3 | 2019 | 830 | 0.150 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 339 | 0.150 |
Why?
|
| Policy | 1 | 2021 | 513 | 0.150 |
Why?
|
| Genome, Viral | 1 | 2021 | 674 | 0.150 |
Why?
|
| Mice, Mutant Strains | 2 | 2016 | 1752 | 0.150 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 381 | 0.140 |
Why?
|
| New York City | 1 | 2020 | 737 | 0.140 |
Why?
|
| Resource Allocation | 1 | 2020 | 354 | 0.140 |
Why?
|
| Leukemia, Myeloid | 5 | 1994 | 693 | 0.140 |
Why?
|
| Sex Factors | 2 | 2021 | 10629 | 0.140 |
Why?
|
| Public Opinion | 1 | 2021 | 485 | 0.140 |
Why?
|
| Cell Cycle Proteins | 3 | 2019 | 3443 | 0.140 |
Why?
|
| Nasopharynx | 1 | 2020 | 420 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 4 | 2019 | 942 | 0.140 |
Why?
|
| Fluoresceins | 1 | 2017 | 235 | 0.140 |
Why?
|
| Tongue | 1 | 2020 | 406 | 0.140 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2018 | 591 | 0.140 |
Why?
|
| Financing, Government | 1 | 2020 | 473 | 0.140 |
Why?
|
| Small Molecule Libraries | 2 | 2019 | 742 | 0.140 |
Why?
|
| Open Reading Frames | 6 | 2006 | 818 | 0.140 |
Why?
|
| Male | 41 | 2024 | 364638 | 0.140 |
Why?
|
| Penicillin V | 1 | 2016 | 18 | 0.140 |
Why?
|
| Benzofurans | 1 | 2017 | 138 | 0.140 |
Why?
|
| Francisella tularensis | 2 | 2007 | 60 | 0.140 |
Why?
|
| Phosphorylation | 5 | 2016 | 8314 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2020 | 549 | 0.140 |
Why?
|
| Amidohydrolases | 1 | 2017 | 160 | 0.130 |
Why?
|
| Breath Tests | 1 | 2018 | 298 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2024 | 780 | 0.130 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 365 | 0.130 |
Why?
|
| Gene Silencing | 2 | 2017 | 1505 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2021 | 8082 | 0.130 |
Why?
|
| Cloning, Molecular | 4 | 2015 | 4168 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7439 | 0.130 |
Why?
|
| Hospital Administration | 1 | 2020 | 351 | 0.130 |
Why?
|
| Receptors, Virus | 1 | 2020 | 652 | 0.130 |
Why?
|
| Nose | 1 | 2020 | 522 | 0.130 |
Why?
|
| Family Characteristics | 1 | 2021 | 1003 | 0.130 |
Why?
|
| Peptidyl Transferases | 1 | 2016 | 55 | 0.130 |
Why?
|
| Cell Line | 8 | 2022 | 15597 | 0.130 |
Why?
|
| Drug Synergism | 4 | 2019 | 1760 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2020 | 1617 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 2024 | 1929 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2023 | 4648 | 0.130 |
Why?
|
| Standard of Care | 1 | 2020 | 569 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2021 | 572 | 0.130 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2019 | 567 | 0.130 |
Why?
|
| Glycosylation | 1 | 2019 | 1100 | 0.130 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 724 | 0.130 |
Why?
|
| Protein Transport | 1 | 2021 | 1951 | 0.130 |
Why?
|
| Substrate Specificity | 3 | 2019 | 1750 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2003 | 1728 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 2021 | 745 | 0.130 |
Why?
|
| Acylation | 2 | 2014 | 98 | 0.130 |
Why?
|
| Safety Management | 1 | 2021 | 765 | 0.130 |
Why?
|
| Advisory Committees | 1 | 2020 | 797 | 0.130 |
Why?
|
| Medical Oncology | 3 | 2017 | 2341 | 0.130 |
Why?
|
| Japan | 1 | 2020 | 1418 | 0.120 |
Why?
|
| Pseudomonas putida | 1 | 2015 | 49 | 0.120 |
Why?
|
| Ferrozine | 1 | 2015 | 1 | 0.120 |
Why?
|
| Child Behavior | 1 | 2021 | 864 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1999 | 681 | 0.120 |
Why?
|
| Cross-Linking Reagents | 1 | 2018 | 693 | 0.120 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2007 | 139 | 0.120 |
Why?
|
| Lactones | 1 | 2017 | 316 | 0.120 |
Why?
|
| Polymyxin B | 1 | 2015 | 44 | 0.120 |
Why?
|
| Benzhydryl Compounds | 3 | 2021 | 944 | 0.120 |
Why?
|
| Occupational Health | 1 | 2021 | 812 | 0.120 |
Why?
|
| Sequence Homology, Amino Acid | 6 | 2015 | 2748 | 0.120 |
Why?
|
| Cell Membrane | 3 | 2024 | 3657 | 0.120 |
Why?
|
| Oxidoreductases | 1 | 2017 | 410 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1999 | 646 | 0.120 |
Why?
|
| Health Facilities | 1 | 2020 | 578 | 0.120 |
Why?
|
| Narcotic Antagonists | 2 | 2013 | 591 | 0.120 |
Why?
|
| Confidence Intervals | 1 | 2020 | 2923 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2023 | 1811 | 0.120 |
Why?
|
| Job Description | 1 | 2014 | 61 | 0.120 |
Why?
|
| Self Care | 1 | 2020 | 799 | 0.120 |
Why?
|
| Phosphatidylethanolamines | 1 | 2015 | 131 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2022 | 42665 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2024 | 1188 | 0.120 |
Why?
|
| Amines | 2 | 2007 | 280 | 0.120 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2016 | 1533 | 0.120 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 381 | 0.120 |
Why?
|
| SELEX Aptamer Technique | 1 | 2014 | 19 | 0.120 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 429 | 0.120 |
Why?
|
| Epsilonproteobacteria | 1 | 2014 | 1 | 0.120 |
Why?
|
| Amide Synthases | 1 | 2014 | 14 | 0.120 |
Why?
|
| India | 1 | 2021 | 2334 | 0.120 |
Why?
|
| Membrane Proteins | 6 | 2019 | 7876 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 524 | 0.120 |
Why?
|
| Sugar Acids | 1 | 2014 | 24 | 0.110 |
Why?
|
| Vaccinia virus | 2 | 2013 | 328 | 0.110 |
Why?
|
| Teichoic Acids | 1 | 2014 | 70 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 3 | 2013 | 1168 | 0.110 |
Why?
|
| Endonucleases | 1 | 2017 | 371 | 0.110 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 119 | 0.110 |
Why?
|
| Gene Order | 1 | 2014 | 166 | 0.110 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 624 | 0.110 |
Why?
|
| Asparagine | 1 | 2014 | 120 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2007 | 451 | 0.110 |
Why?
|
| Risk Factors | 4 | 2022 | 74938 | 0.110 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2014 | 89 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2021 | 10757 | 0.110 |
Why?
|
| Biological Assay | 1 | 2016 | 627 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2953 | 0.110 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2015 | 174 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3601 | 0.110 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2019 | 1276 | 0.110 |
Why?
|
| Motivation | 5 | 2018 | 2020 | 0.110 |
Why?
|
| Physicians | 2 | 2022 | 4598 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 951 | 0.110 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 272 | 0.110 |
Why?
|
| Protein Multimerization | 2 | 2019 | 965 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2020 | 1409 | 0.110 |
Why?
|
| Binding Sites | 6 | 2021 | 6022 | 0.110 |
Why?
|
| Coumarins | 1 | 2013 | 119 | 0.100 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2013 | 117 | 0.100 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2013 | 133 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2014 | 163 | 0.100 |
Why?
|
| Adolescent | 4 | 2022 | 89154 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 2013 | 132 | 0.100 |
Why?
|
| RNA Interference | 5 | 2011 | 2830 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 11068 | 0.100 |
Why?
|
| Brain | 2 | 2018 | 27366 | 0.100 |
Why?
|
| Patient Compliance | 2 | 2022 | 2697 | 0.100 |
Why?
|
| Phylogeny | 4 | 2023 | 2843 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 2456 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2021 | 2117 | 0.100 |
Why?
|
| Zebrafish | 4 | 2021 | 3036 | 0.100 |
Why?
|
| Carrier Proteins | 2 | 2010 | 4937 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2016 | 1972 | 0.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 686 | 0.100 |
Why?
|
| RNA, Untranslated | 2 | 2013 | 455 | 0.100 |
Why?
|
| Organizational Policy | 1 | 2014 | 435 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 430 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 940 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2021 | 1170 | 0.100 |
Why?
|
| Magnesium | 2 | 2015 | 815 | 0.100 |
Why?
|
| Genome | 3 | 2023 | 1754 | 0.100 |
Why?
|
| Adenosine Diphosphate Ribose | 2 | 1989 | 70 | 0.100 |
Why?
|
| Phagocytosis | 2 | 2009 | 1530 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1238 | 0.090 |
Why?
|
| Reward | 1 | 2018 | 981 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 751 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2021 | 2781 | 0.090 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2011 | 10 | 0.090 |
Why?
|
| Gastritis | 1 | 2013 | 199 | 0.090 |
Why?
|
| Immediate-Early Proteins | 3 | 2004 | 444 | 0.090 |
Why?
|
| Psychological Theory | 1 | 2012 | 173 | 0.090 |
Why?
|
| ADP Ribose Transferases | 2 | 1989 | 90 | 0.090 |
Why?
|
| Protein Kinase C | 3 | 1992 | 1207 | 0.090 |
Why?
|
| Salmonella typhimurium | 1 | 2013 | 348 | 0.090 |
Why?
|
| Massachusetts | 1 | 2024 | 8893 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2011 | 11874 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1904 | 0.090 |
Why?
|
| GTP-Binding Proteins | 3 | 1995 | 948 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 4114 | 0.090 |
Why?
|
| Genetic Techniques | 2 | 2017 | 427 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2015 | 915 | 0.090 |
Why?
|
| Cross Infection | 1 | 2020 | 1426 | 0.090 |
Why?
|
| Glutamine | 1 | 2014 | 577 | 0.090 |
Why?
|
| Carbon-Nitrogen Ligases | 1 | 2010 | 27 | 0.090 |
Why?
|
| Chemokines | 2 | 2013 | 963 | 0.090 |
Why?
|
| Naltrexone | 1 | 2013 | 319 | 0.090 |
Why?
|
| Heat Stress Disorders | 2 | 2021 | 80 | 0.090 |
Why?
|
| Signal Transduction | 9 | 2016 | 23640 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 5799 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 321 | 0.090 |
Why?
|
| Games, Experimental | 1 | 2010 | 32 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 6515 | 0.090 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 602 | 0.090 |
Why?
|
| Catalytic Domain | 3 | 2019 | 699 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 20218 | 0.090 |
Why?
|
| Education, Medical | 1 | 2022 | 1742 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2272 | 0.090 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2010 | 68 | 0.080 |
Why?
|
| Epidermis | 1 | 2013 | 539 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2018 | 5904 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 5 | 2015 | 5798 | 0.080 |
Why?
|
| Haemophilus influenzae | 2 | 2002 | 177 | 0.080 |
Why?
|
| NAD | 1 | 2014 | 618 | 0.080 |
Why?
|
| Helicobacter Infections | 1 | 2013 | 390 | 0.080 |
Why?
|
| Risk | 1 | 2022 | 9609 | 0.080 |
Why?
|
| Rabbits | 1 | 2016 | 4771 | 0.080 |
Why?
|
| Transaminases | 1 | 2010 | 199 | 0.080 |
Why?
|
| Etoposide | 1 | 1991 | 640 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 2783 | 0.080 |
Why?
|
| Botulinum Toxins | 2 | 1989 | 191 | 0.080 |
Why?
|
| Research Subjects | 1 | 2011 | 249 | 0.080 |
Why?
|
| Health Behavior | 1 | 2021 | 2650 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2024 | 9384 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 3771 | 0.080 |
Why?
|
| Mycobacterium fortuitum | 2 | 2005 | 6 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2007 | 5023 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 2185 | 0.080 |
Why?
|
| Clostridium botulinum | 2 | 1989 | 21 | 0.080 |
Why?
|
| Decision Making | 1 | 2022 | 3953 | 0.080 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 792 | 0.080 |
Why?
|
| Drug Resistance | 2 | 1994 | 1598 | 0.080 |
Why?
|
| Heart Rate | 7 | 2024 | 4215 | 0.080 |
Why?
|
| Point Mutation | 1 | 1994 | 1594 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 265 | 0.080 |
Why?
|
| Conjugation, Genetic | 2 | 1999 | 116 | 0.080 |
Why?
|
| Models, Biological | 4 | 2018 | 9493 | 0.080 |
Why?
|
| Dopamine Agonists | 1 | 2011 | 347 | 0.080 |
Why?
|
| Aconitate Hydratase | 1 | 2008 | 17 | 0.080 |
Why?
|
| Ethidium | 1 | 2007 | 27 | 0.080 |
Why?
|
| Macaca mulatta | 1 | 2015 | 2364 | 0.080 |
Why?
|
| Drug Tolerance | 3 | 2019 | 365 | 0.080 |
Why?
|
| Pentosyltransferases | 1 | 1988 | 62 | 0.070 |
Why?
|
| Virus Latency | 1 | 2011 | 361 | 0.070 |
Why?
|
| Staphylococcus aureus | 2 | 2014 | 1430 | 0.070 |
Why?
|
| Internship and Residency | 2 | 2021 | 5953 | 0.070 |
Why?
|
| Kinetics | 5 | 2018 | 6328 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2014 | 1189 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3800 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2023 | 3684 | 0.070 |
Why?
|
| Fish Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
| Quinolones | 1 | 2011 | 389 | 0.070 |
Why?
|
| Skin | 1 | 2021 | 4502 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 5 | 2017 | 6232 | 0.070 |
Why?
|
| Transduction, Genetic | 2 | 2009 | 899 | 0.070 |
Why?
|
| Aged | 11 | 2023 | 171453 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2018 | 1969 | 0.070 |
Why?
|
| Carbohydrate Sequence | 1 | 2007 | 411 | 0.070 |
Why?
|
| Critical Care | 1 | 2020 | 2715 | 0.070 |
Why?
|
| Culture Media | 3 | 2014 | 898 | 0.070 |
Why?
|
| Genotype | 1 | 2021 | 13042 | 0.070 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2019 | 161 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2019 | 3079 | 0.070 |
Why?
|
| Molecular Chaperones | 2 | 2022 | 762 | 0.070 |
Why?
|
| Conserved Sequence | 1 | 2010 | 1162 | 0.070 |
Why?
|
| Adhesins, Bacterial | 1 | 2007 | 118 | 0.070 |
Why?
|
| Tularemia | 1 | 2007 | 40 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 3269 | 0.070 |
Why?
|
| Sulfates | 1 | 2007 | 379 | 0.070 |
Why?
|
| Interferons | 1 | 2010 | 720 | 0.070 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2006 | 20 | 0.070 |
Why?
|
| Enzyme Activation | 4 | 2018 | 3587 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2007 | 464 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 22286 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2021 | 4547 | 0.070 |
Why?
|
| Progesterone | 1 | 2010 | 752 | 0.070 |
Why?
|
| Internationality | 2 | 2023 | 1008 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2010 | 840 | 0.070 |
Why?
|
| Autophagy | 2 | 2011 | 1349 | 0.070 |
Why?
|
| Marijuana Abuse | 2 | 2011 | 409 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2022 | 4857 | 0.070 |
Why?
|
| Drosophila melanogaster | 2 | 2005 | 1726 | 0.060 |
Why?
|
| GABA Agonists | 1 | 2006 | 106 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2006 | 205 | 0.060 |
Why?
|
| Lung | 2 | 2023 | 10096 | 0.060 |
Why?
|
| Middle Aged | 18 | 2024 | 223422 | 0.060 |
Why?
|
| Polyketide Synthases | 2 | 2017 | 28 | 0.060 |
Why?
|
| Phenothiazines | 1 | 2005 | 60 | 0.060 |
Why?
|
| RNA Processing, Post-Transcriptional | 3 | 2023 | 393 | 0.060 |
Why?
|
| Genomic Instability | 1 | 2010 | 716 | 0.060 |
Why?
|
| Cisplatin | 1 | 1992 | 1658 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2008 | 462 | 0.060 |
Why?
|
| Cell Survival | 3 | 2008 | 5772 | 0.060 |
Why?
|
| O Antigens | 1 | 2007 | 196 | 0.060 |
Why?
|
| ROC Curve | 1 | 2013 | 3628 | 0.060 |
Why?
|
| Pyrroles | 1 | 2011 | 1123 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1560 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2005 | 95 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2592 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 777 | 0.060 |
Why?
|
| Endosomes | 1 | 2008 | 522 | 0.060 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2006 | 155 | 0.060 |
Why?
|
| Biological Transport | 2 | 2009 | 2085 | 0.060 |
Why?
|
| Silver Staining | 1 | 2004 | 63 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 13000 | 0.060 |
Why?
|
| Heroin Dependence | 1 | 2005 | 173 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 1995 | 287 | 0.060 |
Why?
|
| Genes, Insect | 1 | 2005 | 265 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 9 | 1995 | 6119 | 0.060 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 958 | 0.060 |
Why?
|
| Iron-Binding Proteins | 1 | 2004 | 83 | 0.060 |
Why?
|
| Cell Nucleus | 5 | 2009 | 2881 | 0.060 |
Why?
|
| Aging | 2 | 2024 | 8745 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2011 | 4146 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15443 | 0.060 |
Why?
|
| Embryo, Nonmammalian | 1 | 2007 | 910 | 0.060 |
Why?
|
| Transfection | 3 | 2011 | 5757 | 0.050 |
Why?
|
| Genetic Engineering | 2 | 2008 | 935 | 0.050 |
Why?
|
| Family Leave | 1 | 2023 | 18 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 2 | 2008 | 2634 | 0.050 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2004 | 197 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 170 | 0.050 |
Why?
|
| Listeria monocytogenes | 1 | 2005 | 246 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2004 | 1731 | 0.050 |
Why?
|
| Heterozygote | 1 | 2010 | 2798 | 0.050 |
Why?
|
| Double-Blind Method | 6 | 2021 | 12464 | 0.050 |
Why?
|
| Ethers, Cyclic | 2 | 1993 | 32 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 3055 | 0.050 |
Why?
|
| Methadone | 1 | 2005 | 317 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3238 | 0.050 |
Why?
|
| Temperament | 1 | 2005 | 301 | 0.050 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 2017 | 220 | 0.050 |
Why?
|
| Bacterial Load | 2 | 2014 | 155 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 2013 | 1481 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 2 | 2021 | 842 | 0.050 |
Why?
|
| DNA Primers | 4 | 2012 | 2827 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2005 | 1018 | 0.050 |
Why?
|
| Lac Operon | 1 | 2002 | 237 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5366 | 0.050 |
Why?
|
| Gene Expression Regulation | 5 | 2004 | 11930 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 565 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1543 | 0.050 |
Why?
|
| Ice | 1 | 2023 | 102 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 2065 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 361 | 0.050 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2002 | 177 | 0.050 |
Why?
|
| Vero Cells | 2 | 2021 | 486 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 542 | 0.050 |
Why?
|
| Dimerization | 2 | 2014 | 887 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2024 | 491 | 0.050 |
Why?
|
| Phosphates | 1 | 2005 | 765 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2009 | 3448 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 2005 | 1418 | 0.050 |
Why?
|
| Warfarin | 1 | 2009 | 1493 | 0.050 |
Why?
|
| Salmonella | 1 | 2021 | 125 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 921 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2004 | 1647 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2011 | 4525 | 0.050 |
Why?
|
| Zea mays | 1 | 2001 | 109 | 0.050 |
Why?
|
| Personality Disorders | 1 | 2005 | 726 | 0.040 |
Why?
|
| Drosophila | 2 | 2008 | 1513 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 5505 | 0.040 |
Why?
|
| Professional Role | 1 | 2023 | 315 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 5694 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2011 | 9556 | 0.040 |
Why?
|
| Software | 1 | 2014 | 4479 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2021 | 393 | 0.040 |
Why?
|
| Markov Chains | 2 | 2014 | 980 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2746 | 0.040 |
Why?
|
| Molecular Weight | 3 | 1994 | 2173 | 0.040 |
Why?
|
| Muscidae | 1 | 1999 | 2 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2001 | 1057 | 0.040 |
Why?
|
| Genes, fos | 4 | 1993 | 176 | 0.040 |
Why?
|
| Deoxyadenosines | 1 | 2019 | 27 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2005 | 2627 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2011 | 3472 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2019 | 2487 | 0.040 |
Why?
|
| Mycobacterium kansasii | 1 | 2019 | 8 | 0.040 |
Why?
|
| Database Management Systems | 1 | 2001 | 263 | 0.040 |
Why?
|
| Health Occupations | 1 | 2021 | 225 | 0.040 |
Why?
|
| Cytosol | 2 | 2018 | 887 | 0.040 |
Why?
|
| Intercalating Agents | 1 | 1999 | 33 | 0.040 |
Why?
|
| Token Economy | 2 | 2011 | 17 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2010 | 4176 | 0.040 |
Why?
|
| Rhodobacter capsulatus | 1 | 1999 | 11 | 0.040 |
Why?
|
| Cannabis | 1 | 2006 | 447 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2019 | 289 | 0.040 |
Why?
|
| Biocatalysis | 1 | 2019 | 168 | 0.040 |
Why?
|
| Edeine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 94 | 0.040 |
Why?
|
| Aminoacylation | 1 | 2018 | 9 | 0.040 |
Why?
|
| Propionates | 1 | 2019 | 180 | 0.040 |
Why?
|
| Bacteriophage lambda | 1 | 1999 | 142 | 0.040 |
Why?
|
| Streptomycin | 1 | 2018 | 69 | 0.040 |
Why?
|
| Cyanobacteria | 1 | 1999 | 54 | 0.040 |
Why?
|
| Escherichia coli Vaccines | 1 | 2018 | 10 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2003 | 1494 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2019 | 86 | 0.040 |
Why?
|
| Streptomyces | 1 | 1999 | 91 | 0.040 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 2108 | 0.040 |
Why?
|
| Blood Pressure | 6 | 2011 | 8539 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 15662 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2009 | 4194 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 394 | 0.040 |
Why?
|
| Ethics Committees, Research | 1 | 2020 | 196 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2019 | 328 | 0.040 |
Why?
|
| Health Status | 2 | 2021 | 4092 | 0.040 |
Why?
|
| Bacillus | 1 | 2018 | 77 | 0.040 |
Why?
|
| Aminoacyltransferases | 1 | 2018 | 52 | 0.040 |
Why?
|
| Actins | 3 | 1992 | 2064 | 0.040 |
Why?
|
| Depressive Disorder, Major | 2 | 2024 | 4818 | 0.040 |
Why?
|
| Apoptosis | 2 | 2011 | 9521 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 1 | 2018 | 212 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2018 | 411 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5394 | 0.040 |
Why?
|
| Risk Management | 1 | 2021 | 558 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 16041 | 0.040 |
Why?
|
| Monocytes | 3 | 2013 | 2604 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 1319 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2020 | 422 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1993 | 826 | 0.040 |
Why?
|
| Phenylalanine | 1 | 1999 | 367 | 0.040 |
Why?
|
| Carbazoles | 1 | 1999 | 230 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2018 | 181 | 0.040 |
Why?
|
| Streptococcus thermophilus | 1 | 2017 | 22 | 0.040 |
Why?
|
| Rheumatic Diseases | 1 | 2024 | 659 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 354 | 0.030 |
Why?
|
| DNA Damage | 3 | 1999 | 2470 | 0.030 |
Why?
|
| Caspase 1 | 1 | 2018 | 227 | 0.030 |
Why?
|
| Sequence Alignment | 2 | 2012 | 2178 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1997 | 283 | 0.030 |
Why?
|
| Leucovorin | 1 | 1999 | 644 | 0.030 |
Why?
|
| Employment | 1 | 2023 | 1110 | 0.030 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 1169 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 529 | 0.030 |
Why?
|
| Glioma | 1 | 2011 | 3503 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2017 | 190 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2011 | 800 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2019 | 943 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 17128 | 0.030 |
Why?
|
| Immune Evasion | 1 | 2019 | 375 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2018 | 240 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 1712 | 0.030 |
Why?
|
| Benzoic Acid | 1 | 2015 | 16 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2017 | 571 | 0.030 |
Why?
|
| Fenofibrate | 1 | 1996 | 87 | 0.030 |
Why?
|
| Health Priorities | 1 | 2019 | 380 | 0.030 |
Why?
|
| Epitopes | 1 | 2002 | 2526 | 0.030 |
Why?
|
| Cues | 1 | 2021 | 878 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2011 | 3463 | 0.030 |
Why?
|
| Xenopus | 2 | 2007 | 711 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 4248 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 760 | 0.030 |
Why?
|
| Enterotoxins | 2 | 1995 | 366 | 0.030 |
Why?
|
| Serine | 1 | 1999 | 831 | 0.030 |
Why?
|
| Environment | 1 | 2021 | 1121 | 0.030 |
Why?
|
| Agar | 1 | 2015 | 51 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2002 | 2234 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2004 | 2324 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2014 | 41 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases | 2 | 2011 | 203 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 4423 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 1996 | 305 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 948 | 0.030 |
Why?
|
| Facial Expression | 1 | 2018 | 515 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 4351 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1995 | 363 | 0.030 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2015 | 136 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2020 | 925 | 0.030 |
Why?
|
| Neutropenia | 2 | 2002 | 892 | 0.030 |
Why?
|
| beta-Lactams | 1 | 2016 | 158 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1976 | 0.030 |
Why?
|
| HIV Infections | 1 | 2021 | 17569 | 0.030 |
Why?
|
| Glucosides | 1 | 1999 | 533 | 0.030 |
Why?
|
| Streptococcus pyogenes | 1 | 2017 | 293 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1995 | 121 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 1512 | 0.030 |
Why?
|
| Electron Transport | 1 | 2015 | 211 | 0.030 |
Why?
|
| Species Specificity | 2 | 2009 | 2414 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2020 | 791 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 1999 | 887 | 0.030 |
Why?
|
| Moral Obligations | 1 | 1995 | 91 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2024 | 1944 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2015 | 273 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 651 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2014 | 293 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 2 | 2008 | 377 | 0.030 |
Why?
|
| RNA, Double-Stranded | 2 | 2005 | 292 | 0.030 |
Why?
|
| Medicare | 2 | 2022 | 6814 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2017 | 421 | 0.030 |
Why?
|
| Gene Dosage | 1 | 1998 | 1211 | 0.030 |
Why?
|
| Lysosomes | 1 | 2019 | 938 | 0.030 |
Why?
|
| Biofilms | 1 | 2018 | 634 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1995 | 492 | 0.030 |
Why?
|
| Acute Disease | 1 | 2024 | 7241 | 0.030 |
Why?
|
| Fluorouracil | 1 | 1999 | 1653 | 0.030 |
Why?
|
| Dihydropteroate Synthase | 1 | 2013 | 27 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1992 | 249 | 0.030 |
Why?
|
| Law Enforcement | 1 | 1995 | 112 | 0.030 |
Why?
|
| Peroxynitrous Acid | 1 | 2013 | 40 | 0.030 |
Why?
|
| Clone Cells | 2 | 1994 | 1669 | 0.030 |
Why?
|
| Reactive Nitrogen Species | 1 | 2013 | 35 | 0.030 |
Why?
|
| Skin Diseases, Viral | 1 | 2013 | 26 | 0.030 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2010 | 628 | 0.030 |
Why?
|
| Clostridium | 2 | 1995 | 100 | 0.030 |
Why?
|
| Cattle | 2 | 2011 | 3816 | 0.030 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2015 | 211 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2015 | 246 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 1998 | 764 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2005 | 3721 | 0.030 |
Why?
|
| Vaccinia | 1 | 2013 | 71 | 0.030 |
Why?
|
| Checklist | 1 | 2020 | 843 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 2463 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1992 | 116 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 58 | 0.020 |
Why?
|
| Radiography | 1 | 2023 | 6981 | 0.020 |
Why?
|
| Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2011 | 22 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 2 | 1995 | 279 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2021 | 1791 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 2012 | 137 | 0.020 |
Why?
|
| Reserpine | 1 | 2011 | 63 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2015 | 427 | 0.020 |
Why?
|
| Codon | 1 | 1994 | 599 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 3428 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13500 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2013 | 255 | 0.020 |
Why?
|
| Social Behavior | 1 | 2018 | 1147 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 3729 | 0.020 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2013 | 308 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2013 | 297 | 0.020 |
Why?
|
| Learning | 1 | 2021 | 1759 | 0.020 |
Why?
|
| HIV-1 | 1 | 2009 | 6960 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 1994 | 539 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 1996 | 609 | 0.020 |
Why?
|
| Genomic Library | 1 | 2011 | 189 | 0.020 |
Why?
|
| Diarrhea | 1 | 2018 | 1320 | 0.020 |
Why?
|
| Lipid Bilayers | 1 | 2013 | 379 | 0.020 |
Why?
|
| Behavioral Research | 1 | 2011 | 52 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 806 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2015 | 2857 | 0.020 |
Why?
|
| Inpatients | 1 | 2023 | 2571 | 0.020 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2013 | 265 | 0.020 |
Why?
|
| Threonine | 1 | 2012 | 273 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 56 | 0.020 |
Why?
|
| Verapamil | 1 | 2011 | 242 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2011 | 123 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1993 | 327 | 0.020 |
Why?
|
| Indoles | 1 | 1999 | 1835 | 0.020 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cholera | 1 | 1997 | 754 | 0.020 |
Why?
|
| Motor Activity | 1 | 2021 | 2711 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2013 | 716 | 0.020 |
Why?
|
| Isomerism | 1 | 2010 | 198 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2011 | 699 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 1994 | 1989 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2010 | 219 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2011 | 567 | 0.020 |
Why?
|
| DNA | 2 | 2001 | 7213 | 0.020 |
Why?
|
| Cytoskeleton | 2 | 2005 | 1179 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1995 | 1244 | 0.020 |
Why?
|
| Alcoholism | 1 | 2021 | 1980 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1997 | 1802 | 0.020 |
Why?
|
| DNA, Neoplasm | 2 | 1992 | 1742 | 0.020 |
Why?
|
| Dementia | 1 | 2024 | 2741 | 0.020 |
Why?
|
| RNA, Neoplasm | 4 | 1992 | 748 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2011 | 491 | 0.020 |
Why?
|
| Intestines | 1 | 2018 | 1908 | 0.020 |
Why?
|
| Apolipoproteins B | 1 | 1991 | 385 | 0.020 |
Why?
|
| Smoke | 1 | 2011 | 243 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 828 | 0.020 |
Why?
|
| Rhodococcus | 1 | 2008 | 13 | 0.020 |
Why?
|
| Alcohol-Related Disorders | 1 | 2011 | 243 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 294 | 0.020 |
Why?
|
| Caspases | 1 | 2012 | 882 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1992 | 658 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 579 | 0.020 |
Why?
|
| Travel | 1 | 2014 | 805 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2013 | 876 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1988 | 76 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 753 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 1993 | 8637 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2020 | 19015 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1995 | 1854 | 0.020 |
Why?
|
| Isoenzymes | 1 | 1992 | 1688 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2824 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1991 | 644 | 0.020 |
Why?
|
| Gambling | 1 | 2010 | 192 | 0.020 |
Why?
|
| Genomic Islands | 1 | 2007 | 52 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2008 | 277 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2020 | 6004 | 0.020 |
Why?
|
| Euphoria | 1 | 2007 | 64 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1997 | 4035 | 0.020 |
Why?
|
| Self Report | 1 | 2018 | 3773 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15867 | 0.020 |
Why?
|
| Cyclohexanols | 1 | 2007 | 126 | 0.020 |
Why?
|
| Hormones | 1 | 2010 | 866 | 0.020 |
Why?
|
| Smell | 1 | 2009 | 260 | 0.020 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2008 | 149 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 1988 | 428 | 0.020 |
Why?
|
| Laboratories | 1 | 2010 | 464 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 1074 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2018 | 3703 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2008 | 247 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 1150 | 0.020 |
Why?
|
| Globins | 1 | 1987 | 405 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 2121 | 0.020 |
Why?
|
| Meiosis | 1 | 1988 | 326 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2010 | 825 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2013 | 841 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 1753 | 0.020 |
Why?
|
| Tobacco Use Disorder | 1 | 2011 | 708 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 2004 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2005 | 85 | 0.020 |
Why?
|
| Adenosine | 1 | 2010 | 820 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 2342 | 0.020 |
Why?
|
| Anemia | 1 | 1995 | 1514 | 0.020 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 123 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 2428 | 0.020 |
Why?
|
| Neutrophils | 1 | 2018 | 3786 | 0.020 |
Why?
|
| Transport Vesicles | 1 | 2005 | 79 | 0.010 |
Why?
|
| Vacuoles | 1 | 2005 | 224 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2013 | 2362 | 0.010 |
Why?
|
| Galactans | 1 | 2004 | 31 | 0.010 |
Why?
|
| Genome, Human | 1 | 1997 | 4443 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2011 | 3620 | 0.010 |
Why?
|
| Antibodies, Bacterial | 2 | 2007 | 1478 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2018 | 8740 | 0.010 |
Why?
|
| Acoustic Stimulation | 1 | 2009 | 1254 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 316 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 1992 | 1351 | 0.010 |
Why?
|
| DNA Repair | 1 | 2013 | 2050 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 1999 | 5335 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 2 | 1995 | 133 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2011 | 2936 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2017 | 3591 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 2227 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 3780 | 0.010 |
Why?
|
| Mental Health Services | 1 | 1995 | 1733 | 0.010 |
Why?
|
| Methylphenidate | 1 | 2007 | 480 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1993 | 221 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 897 | 0.010 |
Why?
|
| Okadaic Acid | 2 | 1993 | 67 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 915 | 0.010 |
Why?
|
| Cysteine | 1 | 2007 | 897 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1824 | 0.010 |
Why?
|
| X-Rays | 2 | 1994 | 311 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 2009 | 1998 | 0.010 |
Why?
|
| Dactinomycin | 2 | 1992 | 305 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 705 | 0.010 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2004 | 348 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 2061 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13667 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2005 | 1587 | 0.010 |
Why?
|
| Research | 1 | 2010 | 1979 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 1642 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2014 | 6285 | 0.010 |
Why?
|
| Arousal | 1 | 2007 | 1179 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 2004 | 564 | 0.010 |
Why?
|
| Cell Movement | 1 | 2013 | 5209 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 582 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 1892 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 589 | 0.010 |
Why?
|
| Liver | 1 | 1996 | 7575 | 0.010 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2004 | 582 | 0.010 |
Why?
|
| Patient Admission | 1 | 2007 | 1365 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 1992 | 582 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 11101 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2005 | 1474 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2006 | 1129 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2013 | 5109 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2011 | 6411 | 0.010 |
Why?
|
| Mitochondria | 1 | 2011 | 3681 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 1997 | 120 | 0.010 |
Why?
|
| Ecology | 1 | 1997 | 105 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2007 | 3585 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1996 | 94 | 0.010 |
Why?
|
| Apolipoprotein A-II | 1 | 1996 | 41 | 0.010 |
Why?
|
| Genes, Viral | 1 | 1997 | 655 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29984 | 0.010 |
Why?
|
| Moral Development | 1 | 1995 | 13 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1997 | 473 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 2146 | 0.010 |
Why?
|
| Transferrin | 1 | 1996 | 283 | 0.010 |
Why?
|
| Virus Integration | 1 | 1997 | 307 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 1997 | 562 | 0.010 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 1995 | 83 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 4904 | 0.010 |
Why?
|
| Genes, Immediate-Early | 1 | 1995 | 102 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2819 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 93 | 0.010 |
Why?
|
| Criminal Law | 1 | 1995 | 97 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1996 | 828 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2016 | 41753 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 2906 | 0.010 |
Why?
|
| Pokeweed Mitogens | 1 | 1993 | 38 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1994 | 213 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 1084 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 3710 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1995 | 440 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 1993 | 205 | 0.010 |
Why?
|
| Cesium Radioisotopes | 1 | 1992 | 38 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1992 | 56 | 0.010 |
Why?
|
| Gene Conversion | 1 | 1992 | 69 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1997 | 1207 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1992 | 286 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 14163 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1992 | 341 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 849 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 60050 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1992 | 319 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36743 | 0.010 |
Why?
|
| Isoquinolines | 1 | 1992 | 354 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 4672 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 416 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 1992 | 577 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 2201 | 0.010 |
Why?
|
| Lod Score | 1 | 1991 | 600 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 9116 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 23751 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1992 | 805 | 0.000 |
Why?
|
| Lethal Dose 50 | 1 | 1988 | 71 | 0.000 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1991 | 781 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2004 | 14484 | 0.000 |
Why?
|
| Aged, 80 and over | 2 | 2005 | 59600 | 0.000 |
Why?
|
| Cytotoxins | 1 | 1988 | 154 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1996 | 6225 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5706 | 0.000 |
Why?
|
| Embryonic and Fetal Development | 1 | 1987 | 420 | 0.000 |
Why?
|
| Pregnancy in Diabetics | 1 | 1987 | 198 | 0.000 |
Why?
|
| Cell Differentiation | 2 | 1993 | 11666 | 0.000 |
Why?
|
| Sheep | 1 | 1987 | 1449 | 0.000 |
Why?
|
| Methylation | 1 | 1987 | 1078 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1992 | 3740 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 20757 | 0.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1992 | 1438 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1987 | 1361 | 0.000 |
Why?
|
| Gestational Age | 1 | 1987 | 3622 | 0.000 |
Why?
|
| Infant, Premature | 1 | 1987 | 2124 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1987 | 26418 | 0.000 |
Why?
|